Latest Interferon beta-1a Stories
- Supports US Drug Discovery Activities in Neurodegenerative Diseases- ROCKLAND, Mass., March 30 /PRNewswire/ -- EMD Serono, Inc. announced today that it will open a site in Cambridge, Massachusetts to support its growing Research function.
-- EMD Serono and Fast Forward agree to work together to speed research development on a select group of high potential MS research projects with support of up to $19 million in funding ROCKLAND, Mass.
SAN DIEGO, Feb. 24 /PRNewswire/ -- Ambrx Inc, and Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced a global strategic collaboration to develop and commercialize Ambrx's ARX424 preclinical product candidate for the treatment of multiple sclerosis.
Tysabri is Decision Resources' Gold Standard Through 2017 for Relapsing-Remitting Multiple Sclerosis, According to a New Report from Decision Resources WALTHAM, Mass., Feb.
Theratechnologies (TSX: TH) and EMD Serono Inc., an affiliate of Merck KGaA , Darmstadt Germany, today announced they have entered into a collaboration and licensing agreement for the exclusive commercialization rights to tesamorelin in the United States for the treatment of excess abdominal fat in HIV patients with lipodystrophy.
A drug developed for patients with leukemia also appears to regenerate brain cells and reverse the effects of relapsing-remitting multiple sclerosis, British researchers said on Wednesday.
Genzyme and Bayer have reported Phase II study results demonstrating the potential of alemtuzumab in treatment-naive MS patients.
By Rita Rubin A leukemia drug was about 70% more effective than a standard therapy in treating early multiple sclerosis, according to clinical trial results in today's New England Journal of Medicine.
Genzyme Corporation (Nasdaq: GENZ) and Bayer HealthCare Pharmaceuticals Inc.
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has announced that the ongoing Improve study met its primary endpoint.
- The analysis of literature, focusing on the words and grammar to the exclusion of context or literary merit.